XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 19209

Change

+90.00 (+0.47)%

Market Cap

USD 0.21B

Volume

53.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-0.50 (-0.22%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.02 (+0.01%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.16 (-0.87%)

USD 588.35B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.08 (-0.54%)

USD 588.35B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+1.05 (+1.52%)

USD 266.08B
0QZO:LSE 0QZO

+2.10 (+1.92%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.26 (-0.85%)

USD 244.75B
0QZ3:LSE Qualcomm Inc.

+0.88 (+0.51%)

USD 202.26B
0R24:LSE Intel Corp.

-0.03 (-0.12%)

USD 196.14B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.41% 77% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.41% 77% C+ 71% C-
Trailing 12 Months  
Capital Gain 3.24% 28% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.24% 23% F 37% F
Trailing 5 Years  
Capital Gain 33.44% 55% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.44% 52% F 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.29% 55% F 61% D-
Dividend Return 8.29% 55% F 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.42% 84% B 92% A
Risk Adjusted Return 129.22% 98% N/A 99% N/A
Market Capitalization 0.21B 60% D- 34% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike